Needham & Company LLC reissued their buy rating on shares of Cryoport (NASDAQ:CYRX - Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. Needham & Company LLC currently has a $11.00 price objective on the stock.
A number of other analysts have also issued reports on the company. Roth Mkm reissued a "buy" rating and issued a $15.00 target price on shares of Cryoport in a research report on Tuesday, April 1st. UBS Group lifted their price target on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Finally, Guggenheim initiated coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a "buy" rating and a $11.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $11.83.
Check Out Our Latest Analysis on Cryoport
Cryoport Price Performance
Shares of NASDAQ CYRX traded down $0.11 during mid-day trading on Thursday, reaching $5.55. The company's stock had a trading volume of 310,670 shares, compared to its average volume of 541,673. The stock has a market capitalization of $277.00 million, a P/E ratio of -1.64 and a beta of 1.81. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport has a 1-year low of $4.58 and a 1-year high of $17.55. The stock has a 50-day moving average of $6.09 and a two-hundred day moving average of $7.08.
Cryoport (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The firm had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. On average, equities research analysts anticipate that Cryoport will post -0.99 EPS for the current fiscal year.
Insider Transactions at Cryoport
In related news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at $4,814,359.71. The trade was a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 19,830 shares of company stock worth $118,353 over the last ninety days. 10.10% of the stock is currently owned by company insiders.
Institutional Trading of Cryoport
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. raised its position in shares of Cryoport by 0.4% during the 4th quarter. Franklin Resources Inc. now owns 387,131 shares of the company's stock worth $3,012,000 after purchasing an additional 1,512 shares during the last quarter. Rhumbline Advisers lifted its position in Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock valued at $492,000 after buying an additional 1,764 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. lifted its position in Cryoport by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after acquiring an additional 2,120 shares in the last quarter. Nebula Research & Development LLC grew its stake in shares of Cryoport by 21.6% during the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company's stock valued at $97,000 after acquiring an additional 2,207 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Cryoport by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company's stock valued at $3,144,000 after purchasing an additional 2,226 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company's stock.
Cryoport Company Profile
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Recommended Stories
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
